Combination drug for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination drug, LBL-024, for people with colorectal cancer that has spread to other parts of the body. The goal is to see if the combination can shrink tumors or slow down the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer has spread to other parts of the body (metastatic), and you have at least one tumor that can be measured on a scan.
- You should be physically active enough to do light work (ECOG score 0 or 1), and your doctor expects you to live at least 3 more months.
- Your liver, kidneys, and blood counts must be in good enough shape, based on blood tests.
- If you or your partner can have children, you must agree to use highly effective birth control during treatment and for 6 months after the last dose.
- You cannot be pregnant or breastfeeding, and you cannot have certain medical conditions like active hepatitis B or C, uncontrolled fluid buildup in the chest or belly, or a history of autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial compares two different drug combinations for people with advanced colorectal cancer that has grown after first treatment. It tests whether a newer drug (fruquintinib) combined with standard chemotherapy works as well as the current standard (bevacizumab) combined with chemotherapy.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.